Pregnancy and Vaccination

Pregnancy and vaccination -- maternal immunization -- is the practice of vaccinating during pregnancy to protect both the pregnant person and, through transplacental antibody transfer, the newborn in the early months before infant vaccines take effect. Inactivated vaccines such as influenza and Tdap are central to this strategy, while live attenuated vaccines are generally avoided during pregnancy.

Definition

Maternal immunization is the administration of vaccines during pregnancy to protect the pregnant person and to transfer protective antibody across the placenta to the fetus, providing the newborn with passive immunity in early infancy; it relies on inactivated vaccines and generally avoids live attenuated ones.

Scope

The topic covers the dual rationale of maternal immunization (protecting parent and infant), the mechanism of transplacental IgG transfer, the established roles of inactivated influenza and Tdap vaccines, the general avoidance of live vaccines in pregnancy, and the trial and observational evidence behind these practices. It is reference material on the principles and evidence, not individualized antenatal advice.

Core questions

• How does vaccinating during pregnancy protect the newborn?
• Which vaccines are established for use in pregnancy and which are avoided?
• Why does the timing of maternal vaccination influence infant protection?
• What does trial and observational evidence show about maternal influenza and pertussis vaccination?

Key concepts

• Transplacental IgG antibody transfer
• Dual protection of mother and infant
• Inactivated influenza vaccination in pregnancy
• Tdap (pertussis) vaccination in pregnancy
• General avoidance of live attenuated vaccines in pregnancy
• Passive immunity in early infancy
• Timing of maternal vaccination for optimal antibody transfer

Mechanisms

Maternal vaccination raises the pregnant person's antibody concentrations; immunoglobulin G crosses the placenta actively, so the infant is born with circulating maternal antibody that protects during the first months of life before the infant's own vaccine schedule provides protection. Randomized trials of maternal influenza vaccination demonstrated reductions in laboratory-confirmed influenza in both mothers and infants, establishing proof of concept for the strategy (zaman-2008; madhi-2014). Tdap given in pregnancy raises pertussis-specific antibody that is transferred to the infant, and clinical trial data confirmed its immunogenicity and safety profile in mothers and infants (munoz-2014). Live attenuated vaccines are generally avoided during pregnancy on theoretical grounds related to replicating organisms.

Clinical relevance

Maternal immunization is a means of protecting newborns who are too young to be vaccinated themselves, and understanding its rationale supports interpretation of antenatal vaccination programmes. This entry describes the principles and supporting evidence; it does not provide individualized recommendations, which depend on gestational timing and the specific vaccine.

Epidemiology

Influenza and pertussis cause disproportionate severe disease in young infants, the group maternal immunization aims to protect. Programmatic maternal pertussis vaccination in England was followed by substantial reductions in infant pertussis, providing real-world evidence that complements the randomized trial data (amirthalingam-2014; madhi-2014).

Evidence & guidelines

The evidence base for maternal immunization combines randomized trials and population data. Maternal influenza vaccine trials showed protection of mothers and infants (zaman-2008; madhi-2014); a randomized trial established the immunogenicity and safety of antenatal Tdap (munoz-2014); and observational programme data from England demonstrated effectiveness of maternal pertussis vaccination against infant disease (amirthalingam-2014). Standard vaccinology references synthesise the principles and the general avoidance of live vaccines in pregnancy (plotkin-2018).

History

Maternal immunization built on the long-standing observation that maternal antibody protects newborns, formalised through tetanus toxoid programmes and then extended by twenty-first-century trials of maternal influenza and pertussis vaccination. The influenza trials of Zaman and colleagues and Madhi and colleagues, and the Tdap trial of Munoz and colleagues, together with England's programmatic pertussis data, consolidated maternal immunization as an evidence-based strategy (zaman-2008; madhi-2014; munoz-2014; amirthalingam-2014).

Debates

Could high maternal antibody blunt the infant's own vaccine responses?

Whether maternally transferred antibody modestly interferes with the infant's response to its own early vaccinations has been examined and weighed against the clear benefit of early passive protection; it remains a nuance considered in programme design rather than a reason to withhold maternal vaccination.

Key figures

• Flor Munoz
• Shabir Madhi
• Mark Steinhoff
• Gayatri Amirthalingam

Seminal works

• zaman-2008
• madhi-2014
• munoz-2014

Frequently asked questions

How does vaccinating during pregnancy protect a newborn?

Maternal vaccination raises the pregnant person's antibody levels, and immunoglobulin G crosses the placenta to the fetus, so the infant is born with maternal antibody that provides passive protection in the first months before its own vaccines take effect.

Why are live vaccines generally avoided in pregnancy?

Live attenuated vaccines contain replicating organisms and are generally avoided during pregnancy on theoretical safety grounds, so maternal immunization relies on inactivated vaccines such as influenza and Tdap.